αiI-spectrin breakdown products (SBDPs): Diagnosis and outcome in severe traumatic brain injury patients

Stefania Mondello, Steven A. Robicsek, Andrea Gabrielli, Gretchen M. Brophy, Linda Papa, Joseph Tepas, Claudia Robertson, A. Büki, Dancia Scharf, Mo Jixiang, Linnet Akinyi, Uwe Muller, Kevin K W Wang, Ronald L. Hayes

Research output: Contribution to journalArticle

117 Citations (Scopus)

Abstract

In this study we assessed the clinical utility of quantitative assessments of αII-spectrin breakdown products (SBDP145 produced by calpain, and SBDP120 produced by caspase-3) in cerebrospinal fluid (CSF) as markers of brain damage and outcome after severe traumatic brain injury (TBI). We analyzed 40 adult patients with severe TBI (Glasgow Coma Scale [GCS] score ≤8) who underwent ventriculostomy. Patients requiring CSF drainage for other medical reasons served as controls. CSF samples were taken at admission and every 6h thereafter for a maximum of 7 days and assessed using novel quantitative fragment-specific ELISAs for SBDPs. Outcome was assessed using the 3-month Glasgow Outcome Scale. Mean CSF levels of SBDPs were significantly higher in TBI patients than in controls at all time points examined. Different temporal release patterns of CSF SBDP145 and SBDP120 were observed. SBDP145 provided accurate diagnoses at all time points examined, while SBDP120 release was more accurate 24h after injury. Within 24h after injury, SBDP145 CSF concentrations significantly correlated with GCS scores, while SBDP120 levels correlated with age. SBDP levels were significantly higher in patients who died than in those who survived. SBDP145 levels (>6ng/mL) and SBDP120 levels (>17.55ng/mL) strongly predicted death (odds ratio 5.9 for SBDP145, and 18.34 for SBDP120). The time course of SBDPs in nonsurvivors also differed from that of survivors. These results suggest that CSF SBDP levels can predict injury severity and mortality after severe TBI, and can be useful complements to clinical assessment.

Original languageEnglish
Pages (from-to)1203-1213
Number of pages11
JournalJournal of Neurotrauma
Volume27
Issue number7
DOIs
Publication statusPublished - Jul 1 2010

Fingerprint

Spectrin
Cerebrospinal Fluid
Glasgow Coma Scale
Wounds and Injuries
Ventriculostomy
Glasgow Outcome Scale
Calpain
Caspase 3
Survivors
Traumatic Brain Injury
Enzyme-Linked Immunosorbent Assay
Odds Ratio
Mortality
Brain

Keywords

  • biomarkers
  • brain injury
  • diagnostic
  • neuronal death
  • outcome
  • spectrin breakdown products

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Mondello, S., Robicsek, S. A., Gabrielli, A., Brophy, G. M., Papa, L., Tepas, J., ... Hayes, R. L. (2010). αiI-spectrin breakdown products (SBDPs): Diagnosis and outcome in severe traumatic brain injury patients. Journal of Neurotrauma, 27(7), 1203-1213. https://doi.org/10.1089/neu.2010.1278

αiI-spectrin breakdown products (SBDPs) : Diagnosis and outcome in severe traumatic brain injury patients. / Mondello, Stefania; Robicsek, Steven A.; Gabrielli, Andrea; Brophy, Gretchen M.; Papa, Linda; Tepas, Joseph; Robertson, Claudia; Büki, A.; Scharf, Dancia; Jixiang, Mo; Akinyi, Linnet; Muller, Uwe; Wang, Kevin K W; Hayes, Ronald L.

In: Journal of Neurotrauma, Vol. 27, No. 7, 01.07.2010, p. 1203-1213.

Research output: Contribution to journalArticle

Mondello, S, Robicsek, SA, Gabrielli, A, Brophy, GM, Papa, L, Tepas, J, Robertson, C, Büki, A, Scharf, D, Jixiang, M, Akinyi, L, Muller, U, Wang, KKW & Hayes, RL 2010, 'αiI-spectrin breakdown products (SBDPs): Diagnosis and outcome in severe traumatic brain injury patients', Journal of Neurotrauma, vol. 27, no. 7, pp. 1203-1213. https://doi.org/10.1089/neu.2010.1278
Mondello, Stefania ; Robicsek, Steven A. ; Gabrielli, Andrea ; Brophy, Gretchen M. ; Papa, Linda ; Tepas, Joseph ; Robertson, Claudia ; Büki, A. ; Scharf, Dancia ; Jixiang, Mo ; Akinyi, Linnet ; Muller, Uwe ; Wang, Kevin K W ; Hayes, Ronald L. / αiI-spectrin breakdown products (SBDPs) : Diagnosis and outcome in severe traumatic brain injury patients. In: Journal of Neurotrauma. 2010 ; Vol. 27, No. 7. pp. 1203-1213.
@article{8f0edd0be17b433eb81310408ff39d28,
title = "αiI-spectrin breakdown products (SBDPs): Diagnosis and outcome in severe traumatic brain injury patients",
abstract = "In this study we assessed the clinical utility of quantitative assessments of αII-spectrin breakdown products (SBDP145 produced by calpain, and SBDP120 produced by caspase-3) in cerebrospinal fluid (CSF) as markers of brain damage and outcome after severe traumatic brain injury (TBI). We analyzed 40 adult patients with severe TBI (Glasgow Coma Scale [GCS] score ≤8) who underwent ventriculostomy. Patients requiring CSF drainage for other medical reasons served as controls. CSF samples were taken at admission and every 6h thereafter for a maximum of 7 days and assessed using novel quantitative fragment-specific ELISAs for SBDPs. Outcome was assessed using the 3-month Glasgow Outcome Scale. Mean CSF levels of SBDPs were significantly higher in TBI patients than in controls at all time points examined. Different temporal release patterns of CSF SBDP145 and SBDP120 were observed. SBDP145 provided accurate diagnoses at all time points examined, while SBDP120 release was more accurate 24h after injury. Within 24h after injury, SBDP145 CSF concentrations significantly correlated with GCS scores, while SBDP120 levels correlated with age. SBDP levels were significantly higher in patients who died than in those who survived. SBDP145 levels (>6ng/mL) and SBDP120 levels (>17.55ng/mL) strongly predicted death (odds ratio 5.9 for SBDP145, and 18.34 for SBDP120). The time course of SBDPs in nonsurvivors also differed from that of survivors. These results suggest that CSF SBDP levels can predict injury severity and mortality after severe TBI, and can be useful complements to clinical assessment.",
keywords = "biomarkers, brain injury, diagnostic, neuronal death, outcome, spectrin breakdown products",
author = "Stefania Mondello and Robicsek, {Steven A.} and Andrea Gabrielli and Brophy, {Gretchen M.} and Linda Papa and Joseph Tepas and Claudia Robertson and A. B{\"u}ki and Dancia Scharf and Mo Jixiang and Linnet Akinyi and Uwe Muller and Wang, {Kevin K W} and Hayes, {Ronald L.}",
year = "2010",
month = "7",
day = "1",
doi = "10.1089/neu.2010.1278",
language = "English",
volume = "27",
pages = "1203--1213",
journal = "Journal of Neurotrauma",
issn = "0897-7151",
publisher = "Mary Ann Liebert Inc.",
number = "7",

}

TY - JOUR

T1 - αiI-spectrin breakdown products (SBDPs)

T2 - Diagnosis and outcome in severe traumatic brain injury patients

AU - Mondello, Stefania

AU - Robicsek, Steven A.

AU - Gabrielli, Andrea

AU - Brophy, Gretchen M.

AU - Papa, Linda

AU - Tepas, Joseph

AU - Robertson, Claudia

AU - Büki, A.

AU - Scharf, Dancia

AU - Jixiang, Mo

AU - Akinyi, Linnet

AU - Muller, Uwe

AU - Wang, Kevin K W

AU - Hayes, Ronald L.

PY - 2010/7/1

Y1 - 2010/7/1

N2 - In this study we assessed the clinical utility of quantitative assessments of αII-spectrin breakdown products (SBDP145 produced by calpain, and SBDP120 produced by caspase-3) in cerebrospinal fluid (CSF) as markers of brain damage and outcome after severe traumatic brain injury (TBI). We analyzed 40 adult patients with severe TBI (Glasgow Coma Scale [GCS] score ≤8) who underwent ventriculostomy. Patients requiring CSF drainage for other medical reasons served as controls. CSF samples were taken at admission and every 6h thereafter for a maximum of 7 days and assessed using novel quantitative fragment-specific ELISAs for SBDPs. Outcome was assessed using the 3-month Glasgow Outcome Scale. Mean CSF levels of SBDPs were significantly higher in TBI patients than in controls at all time points examined. Different temporal release patterns of CSF SBDP145 and SBDP120 were observed. SBDP145 provided accurate diagnoses at all time points examined, while SBDP120 release was more accurate 24h after injury. Within 24h after injury, SBDP145 CSF concentrations significantly correlated with GCS scores, while SBDP120 levels correlated with age. SBDP levels were significantly higher in patients who died than in those who survived. SBDP145 levels (>6ng/mL) and SBDP120 levels (>17.55ng/mL) strongly predicted death (odds ratio 5.9 for SBDP145, and 18.34 for SBDP120). The time course of SBDPs in nonsurvivors also differed from that of survivors. These results suggest that CSF SBDP levels can predict injury severity and mortality after severe TBI, and can be useful complements to clinical assessment.

AB - In this study we assessed the clinical utility of quantitative assessments of αII-spectrin breakdown products (SBDP145 produced by calpain, and SBDP120 produced by caspase-3) in cerebrospinal fluid (CSF) as markers of brain damage and outcome after severe traumatic brain injury (TBI). We analyzed 40 adult patients with severe TBI (Glasgow Coma Scale [GCS] score ≤8) who underwent ventriculostomy. Patients requiring CSF drainage for other medical reasons served as controls. CSF samples were taken at admission and every 6h thereafter for a maximum of 7 days and assessed using novel quantitative fragment-specific ELISAs for SBDPs. Outcome was assessed using the 3-month Glasgow Outcome Scale. Mean CSF levels of SBDPs were significantly higher in TBI patients than in controls at all time points examined. Different temporal release patterns of CSF SBDP145 and SBDP120 were observed. SBDP145 provided accurate diagnoses at all time points examined, while SBDP120 release was more accurate 24h after injury. Within 24h after injury, SBDP145 CSF concentrations significantly correlated with GCS scores, while SBDP120 levels correlated with age. SBDP levels were significantly higher in patients who died than in those who survived. SBDP145 levels (>6ng/mL) and SBDP120 levels (>17.55ng/mL) strongly predicted death (odds ratio 5.9 for SBDP145, and 18.34 for SBDP120). The time course of SBDPs in nonsurvivors also differed from that of survivors. These results suggest that CSF SBDP levels can predict injury severity and mortality after severe TBI, and can be useful complements to clinical assessment.

KW - biomarkers

KW - brain injury

KW - diagnostic

KW - neuronal death

KW - outcome

KW - spectrin breakdown products

UR - http://www.scopus.com/inward/record.url?scp=77955077424&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955077424&partnerID=8YFLogxK

U2 - 10.1089/neu.2010.1278

DO - 10.1089/neu.2010.1278

M3 - Article

C2 - 20408766

AN - SCOPUS:77955077424

VL - 27

SP - 1203

EP - 1213

JO - Journal of Neurotrauma

JF - Journal of Neurotrauma

SN - 0897-7151

IS - 7

ER -